Muhammad Hassan Waseem, Zain Ul Abideen, Marium Khan, Barka Sajid, Noor Ul Huda Ramzan, Rabeya Farid, Javed Iqbal, Jalib Ahmed, Aqsa Kabir, Maryam Shahzad, Javeria Asif, Muhammad Osama, Sania Aimen, Ammad Javaid Chaudhary, Ameer Haider Cheema
{"title":"抗凝剂在肝硬化和门静脉血栓患者中的疗效和安全性：随机和非随机研究的系统回顾和荟萃分析","authors":"Muhammad Hassan Waseem, Zain Ul Abideen, Marium Khan, Barka Sajid, Noor Ul Huda Ramzan, Rabeya Farid, Javed Iqbal, Jalib Ahmed, Aqsa Kabir, Maryam Shahzad, Javeria Asif, Muhammad Osama, Sania Aimen, Ammad Javaid Chaudhary, Ameer Haider Cheema","doi":"10.1002/jgh3.70194","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Portal vein thrombosis (PVT) contributes substantially to morbidity and mortality in cirrhotic patients. A clear insight into the anticoagulation therapy benefits in these patients could improve clinical decision-making. This meta-analysis aimed to assess the efficacy and safety of Anticoagulants in cirrhotic patients with PVT.</p><p><strong>Methods: </strong>PubMed, Cochrane Library, and ScienceDirect were searched from inception to September 2024. The Risk Ratios (RR) with 95% Confidence Interval (CI) were pooled for dichotomous outcomes under the random effects model using Review Manager 5.4.1. The primary endpoint of interest is PVT recanalization. Quality assessment was done through the Newcastle Ottawa Scale and the Cochrane RoB2.0 tool. Leave-one-out sensitivity analysis was done to investigate the cause of heterogeneity. Publication bias was assessed through funnel plots.</p><p><strong>Results: </strong>Twenty-three studies (including 19 cohorts and 4 Randomized trials), pooling 81,599 patients, were included in the analysis. Anticoagulants significantly increased the PVT recanalization (RR = 2.00; 95% CI: [1.59, 2.52]; <i>p</i> < 0.00001; <i>I</i> <sup>2</sup> = 13%), PVT improvement (RR = 1.98; 95% CI: [1.70, 2.29], <i>p</i> < 0.00001; <i>I</i> <sup>2</sup> = 0%) while decreasing the PVT stability (RR = 0.78; 95% CI: [0.62,0.99], <i>p</i> = 0.04; <i>I</i> <sup>2</sup> = 19%) and PVT progression (RR = 0.42; 95% CI: [0.29, 0.60], <i>p</i> < 0.00001; <i>I</i> <sup>2</sup> = 27%). Other outcomes including mortality (RR = 0.53; 95% CI: [0.27, 1.03]; <i>p</i> = 0.06; <i>I</i> <sup>2</sup> = 94%), total bleeding (RR = 1.02; 95% CI: [0.76, 1.37], <i>p</i> = 0.89; <i>I</i> <sup>2</sup> = 31%), esophageal variceal bleeding (RR = 0.74; 95% CI: [0.54, 1.01], <i>p</i> = 0.06; <i>I</i> <sup>2</sup> = 56%), Gastrointestinal bleeding (RR = 1.07; 95% CI: [0.78, 1.48]; <i>p</i> = 0.66, <i>I</i> <sup>2</sup> = 13%) and Intracranial hemorrhage (RR = 1.19; 95% CI: [0.89, 1.58], <i>p</i> = 0.24, <i>I</i> <sup>2</sup> = 0%) were comparable between the 2 arms.</p><p><strong>Conclusion: </strong>Anticoagulants significantly increased PVT recanalization and PVT improvement while decreasing PVT stability and PVT progression in cirrhotic patients. Other outcomes were comparable between the two groups.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"9 8","pages":"e70194"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333073/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies.\",\"authors\":\"Muhammad Hassan Waseem, Zain Ul Abideen, Marium Khan, Barka Sajid, Noor Ul Huda Ramzan, Rabeya Farid, Javed Iqbal, Jalib Ahmed, Aqsa Kabir, Maryam Shahzad, Javeria Asif, Muhammad Osama, Sania Aimen, Ammad Javaid Chaudhary, Ameer Haider Cheema\",\"doi\":\"10.1002/jgh3.70194\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Portal vein thrombosis (PVT) contributes substantially to morbidity and mortality in cirrhotic patients. A clear insight into the anticoagulation therapy benefits in these patients could improve clinical decision-making. This meta-analysis aimed to assess the efficacy and safety of Anticoagulants in cirrhotic patients with PVT.</p><p><strong>Methods: </strong>PubMed, Cochrane Library, and ScienceDirect were searched from inception to September 2024. The Risk Ratios (RR) with 95% Confidence Interval (CI) were pooled for dichotomous outcomes under the random effects model using Review Manager 5.4.1. The primary endpoint of interest is PVT recanalization. Quality assessment was done through the Newcastle Ottawa Scale and the Cochrane RoB2.0 tool. Leave-one-out sensitivity analysis was done to investigate the cause of heterogeneity. Publication bias was assessed through funnel plots.</p><p><strong>Results: </strong>Twenty-three studies (including 19 cohorts and 4 Randomized trials), pooling 81,599 patients, were included in the analysis. Anticoagulants significantly increased the PVT recanalization (RR = 2.00; 95% CI: [1.59, 2.52]; <i>p</i> < 0.00001; <i>I</i> <sup>2</sup> = 13%), PVT improvement (RR = 1.98; 95% CI: [1.70, 2.29], <i>p</i> < 0.00001; <i>I</i> <sup>2</sup> = 0%) while decreasing the PVT stability (RR = 0.78; 95% CI: [0.62,0.99], <i>p</i> = 0.04; <i>I</i> <sup>2</sup> = 19%) and PVT progression (RR = 0.42; 95% CI: [0.29, 0.60], <i>p</i> < 0.00001; <i>I</i> <sup>2</sup> = 27%). Other outcomes including mortality (RR = 0.53; 95% CI: [0.27, 1.03]; <i>p</i> = 0.06; <i>I</i> <sup>2</sup> = 94%), total bleeding (RR = 1.02; 95% CI: [0.76, 1.37], <i>p</i> = 0.89; <i>I</i> <sup>2</sup> = 31%), esophageal variceal bleeding (RR = 0.74; 95% CI: [0.54, 1.01], <i>p</i> = 0.06; <i>I</i> <sup>2</sup> = 56%), Gastrointestinal bleeding (RR = 1.07; 95% CI: [0.78, 1.48]; <i>p</i> = 0.66, <i>I</i> <sup>2</sup> = 13%) and Intracranial hemorrhage (RR = 1.19; 95% CI: [0.89, 1.58], <i>p</i> = 0.24, <i>I</i> <sup>2</sup> = 0%) were comparable between the 2 arms.</p><p><strong>Conclusion: </strong>Anticoagulants significantly increased PVT recanalization and PVT improvement while decreasing PVT stability and PVT progression in cirrhotic patients. Other outcomes were comparable between the two groups.</p>\",\"PeriodicalId\":45861,\"journal\":{\"name\":\"JGH Open\",\"volume\":\"9 8\",\"pages\":\"e70194\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333073/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JGH Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/jgh3.70194\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/jgh3.70194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Efficacy and Safety of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies.
Background: Portal vein thrombosis (PVT) contributes substantially to morbidity and mortality in cirrhotic patients. A clear insight into the anticoagulation therapy benefits in these patients could improve clinical decision-making. This meta-analysis aimed to assess the efficacy and safety of Anticoagulants in cirrhotic patients with PVT.
Methods: PubMed, Cochrane Library, and ScienceDirect were searched from inception to September 2024. The Risk Ratios (RR) with 95% Confidence Interval (CI) were pooled for dichotomous outcomes under the random effects model using Review Manager 5.4.1. The primary endpoint of interest is PVT recanalization. Quality assessment was done through the Newcastle Ottawa Scale and the Cochrane RoB2.0 tool. Leave-one-out sensitivity analysis was done to investigate the cause of heterogeneity. Publication bias was assessed through funnel plots.
Results: Twenty-three studies (including 19 cohorts and 4 Randomized trials), pooling 81,599 patients, were included in the analysis. Anticoagulants significantly increased the PVT recanalization (RR = 2.00; 95% CI: [1.59, 2.52]; p < 0.00001; I2 = 13%), PVT improvement (RR = 1.98; 95% CI: [1.70, 2.29], p < 0.00001; I2 = 0%) while decreasing the PVT stability (RR = 0.78; 95% CI: [0.62,0.99], p = 0.04; I2 = 19%) and PVT progression (RR = 0.42; 95% CI: [0.29, 0.60], p < 0.00001; I2 = 27%). Other outcomes including mortality (RR = 0.53; 95% CI: [0.27, 1.03]; p = 0.06; I2 = 94%), total bleeding (RR = 1.02; 95% CI: [0.76, 1.37], p = 0.89; I2 = 31%), esophageal variceal bleeding (RR = 0.74; 95% CI: [0.54, 1.01], p = 0.06; I2 = 56%), Gastrointestinal bleeding (RR = 1.07; 95% CI: [0.78, 1.48]; p = 0.66, I2 = 13%) and Intracranial hemorrhage (RR = 1.19; 95% CI: [0.89, 1.58], p = 0.24, I2 = 0%) were comparable between the 2 arms.
Conclusion: Anticoagulants significantly increased PVT recanalization and PVT improvement while decreasing PVT stability and PVT progression in cirrhotic patients. Other outcomes were comparable between the two groups.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
